Ranbaxy Announces Settlement of Possible Imitrex Litigation With GlaxoSmithKline

Ranbaxy Announces Settlement of Possible Imitrex Litigation With GlaxoSmithKline

PRINCETON, N.J., Jan. 21 -- Ranbaxy Laboratories Limited (Ranbaxy) announced today that it has settled all matters relating to possible patent litigation with GlaxoSmithKline relating to Sumatriptan Succinate Tablets, the generic version of GlaxoSmithKline's Imitrex(R) Tablets.

The terms of the settlement provide that Ranbaxy may distribute a generic version of Sumatriptan Succinate Tablets (in the 25 mg, 50 mg and 100 mg strengths) in the United States with an expected launch date in December, 2008.

Additional terms of the settlement agreement were not disclosed.

The annual market sales for Sumatriptan Succinate (Imitrex(R)) were USD 985 million (IMS-MAT: Sept 2007).

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.

CONTACTS: Charles M. Caprariello Edwige Buteau Vice President, Corporate Communications RF Binder Partners Inc.

Ranbaxy Inc. (917) 655-3843 (609) 720-5615 Anuj Baveja RF Binder Partners Inc.

(551) 587-2233

DATASOURCE: Ranbaxy Laboratories Limited


CONTACT: Charles M. Caprariello, Vice President, Corporate

Communications, Ranbaxy Inc., +1-609-720-5615, or Edwige Buteau,

+1-917-655-3843, or Anuj Baveja, +1-551-587-2233, both of RF Binder Partners

Inc. for Ranbaxy Inc.

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.